VANCOUVER,
April 2, 2015 /PRNewswire/ -
RepliCel Life Sciences Inc. (the "Company" or "RepliCel")
(OTCQB: REPCF) (TSX.V: RP), a clinical stage
regenerative medicine company focused on the development of
autologous cell therapies, today announced that it has applied to
the TSX Venture Exchange to extend the term of 2,043,555 share
purchase warrants (the "Warrants"). The original term of
1,643,555 of the Warrants was two years and expires on April 10, 2015 and the original term of 400,000
of the Warrants was two years and expires on May 21, 2015. The Company proposes to extend
the expiry date for a period of one year to April 10, 2016 for 1,643,555 of the Warrants and
to May 21, 2016 for 400,000 of the
Warrants. In all other respects the terms of the Warrants will
remain unchanged and in full force and effect.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that address diseases caused by a deficit
of healthy cells required for normal healing and function. The
company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to
treat chronic tendinosis, damaged or aging skin, and pattern
baldness. All product candidates are based on RepliCel's innovative
technology utilizing cell populations isolated from a patient's own
healthy hair follicles. The company is also developing a propriety
injection device optimized for the administration of its products
and licensable for use with other dermatology
applications. The company's product pipeline is comprised of
multiple clinical trials anticipated to launch through Q1 2015 in
addition to Shiseido's own clinical trial of RCH-01 and the device
in late prototype development. Visit www.replicel.com for
additional information.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE RepliCel Life Sciences Inc.